Methods of treating disorders associated with castor

Abstract

The present disclosure relates to methods of treating a coenzyme A reduction, elevation, sequestration, toxicity, or redistribution (CASTOR) disease such as, for example, defects in fatty acid oxidation enzymes, methylmalonic acidemia, glutaric acidemia, propionic academia, and HMG-CoA lyase, via small molecule modulators of CoA levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

1 . (canceled) 
     
     
         2 . A method of treating methylmalonic acidemia (MMA) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound represented by a formula: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, 
         wherein:
 A is CH 2 ; 
 Q 1  is CH; and R 2  is selected from —SCH 3 , C1-C8 acyclic alkyl, C2-C8 acyclic alkenyl, C1-C8 monohaloalkyl, C1-C8 polyhaloalkyl, C1-C8 alkoxyhaloalkyl, cyclopropyl, cyclobutyl, and oxetane, wherein the cyclopropyl, cyclobutyl, and oxetane are optionally substituted with 1, 2, or 3 groups independently selected from —OH, C1-C4 alkyl, and C1-C4 alkoxy; or 
 Q 1  is N; and R 2  is selected from halogen, —SCH 3 , C1-C8 acyclic alkyl, C2-C8 acyclic alkenyl, C1-C8 monohaloalkyl, C1-C8 polyhaloalkyl, C1-C8 alkoxyhaloalkyl, cyclopropyl, cyclobutyl, and oxetane, wherein the cyclopropyl, cyclobutyl, and oxetane are optionally substituted with 1, 2, or 3 groups independently selected from —OH, C1-C4 alkyl, and C1-C4 alkoxy; 
 Q 2  is a structure selected from: 
 
       
       
         
           
           
               
               
           
         
          each of R 3a  and R 3b  is independently selected from hydrogen, halogen, —OH, C1-C4 alkoxy, and C1-C4 alkyl; and 
          R 23  is selected from halogen and —CN. 
       
     
     
         3 . The method of  claim 2 , wherein the compound has a structure represented by a formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         4 - 5 . (canceled) 
     
     
         6 . The method of  claim 2 , wherein the compound is selected from: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         7 - 28 . (canceled) 
     
     
         29 . The method of  claim 2 , wherein the subject is a mammal. 
     
     
         30 . The method of  claim 2 , wherein the mammal is a human. 
     
     
         31 - 32 . (canceled) 
     
     
         33 . The method of  claim 2 , further comprising the step of administering to the subject a therapeutically effective amount of carnitine, pantothenate, and/or pantothenic acid. 
     
     
         34 . The method of  claim 2 , wherein the MMA is hereditary. 
     
     
         35 . The method of  claim 2 , wherein the MMA is acquired. 
     
     
         36 . A kit for treating methylmalonic acidemia (MMA) in a subject in need thereof, comprising:
 (a) an effective amount of a compound of  claim 2 ; and   (b) at least one agent known to treat MMA,   together with instructions for effective administration.   
     
     
         37 . (canceled) 
     
     
         38 . The kit of  claim 36 , wherein the at least one agent is carnitine, pantothenate, or pantothenic acid. 
     
     
         39 . The kit of  claim 36 , wherein the compound is represented by the formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         40 . The kit of  claim 36 , wherein the compound is represented by the formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         41 . The kit of  claim 36 , wherein the compound is represented by the formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         42 . The method of  claim 2 , wherein Q 1  is CH. 
     
     
         43 . The method of  claim 2 , wherein R 2  is cyclopropyl. 
     
     
         44 . The method of  claim 2 , wherein Q 2  is a structure: 
       
         
           
           
               
               
           
         
       
     
     
         45 . The method of  claim 2 , wherein the compound is represented by the formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         46 . The method of  claim 2 , wherein the compound is represented by the formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         47 . The method of  claim 2 , wherein the compound is represented by the formula: 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof.